Report Contents
Market Overview
The global continuous glucose monitoring (CGM) market is entering a high-growth phase, with revenue projected to reach about 15,10 Billion in 2026 and expand at a 10.20% CAGR through 2032. This acceleration reflects rising diabetes prevalence, greater adoption of real-time glucose analytics, and payer shifts toward outcomes-based reimbursement, which together are reshaping how CGM solutions are designed, priced, and deployed across regions.
Within this landscape, scalability of device platforms, localization of user experience and regulatory strategies, and deep technological integration with insulin delivery systems, smartphones, and cloud analytics emerge as core strategic imperatives. Converging trends such as sensor miniaturization, factory calibration, interoperability standards, and data-driven population health management are broadening the addressable market while redefining future competitive dynamics. Positioned against this backdrop, this report serves as an essential strategic tool, providing forward-looking analysis to guide capital allocation, partnership choices, and market entry decisions amid accelerating innovation and structural disruption.
Market Growth Timeline (USD Billion)
Source: Secondary Information and ReportMines Research Team - 2026
Market Segmentation
The CGM Market analysis has been structured and segmented according to type, application, geographic region and key competitors to provide a comprehensive view of the industry landscape.
Key Product Application Covered
Key Product Types Covered
Key Companies Covered
By Type
The Global CGM Market is primarily segmented into several key types, each designed to address specific operational demands and performance criteria.
-
Wearable CGM sensors:
Wearable CGM sensors currently represent the most visible and widely adopted component of the global CGM ecosystem, anchoring a significant portion of the overall market value projected to reach USD 13,70 billion in 2025. These subcutaneous sensors provide near real-time glucose measurements at intervals as frequent as every 1–5 minutes, enabling continuous glycemic profiling that far surpasses traditional fingerstick testing. Their market position is reinforced by strong patient adherence, as wear times have extended from a few days in early-generation products to up to 10–14 days in leading systems, reducing device turnover and improving convenience.
The core competitive advantage of wearable CGM sensors lies in their accuracy and sensor longevity, which directly influence therapeutic decision-making and payer adoption. Many current-generation sensors achieve a mean absolute relative difference around the low double-digit percent range, with some platforms demonstrating time-in-range improvements of over 10–20 percentage points when patients transition from self-monitoring of blood glucose to CGM-guided therapy. The primary catalyst driving growth for this segment is the convergence of miniaturized biosensing, improved enzyme chemistry, and expanded reimbursement coverage, which together are accelerating penetration across both type 1 and insulin-treated type 2 diabetes populations.
As health systems increasingly focus on outcome-based reimbursement, wearable CGM sensors benefit from quantifiable reductions in acute complications such as severe hypoglycemia and diabetic ketoacidosis. Clinical programs that deploy these sensors at scale have reported reductions in hospitalizations and emergency visits that translate into double-digit percentage cost savings per patient-year, making them attractive for payers managing large diabetic cohorts. This strong value proposition, supported by an estimated global CGM market CAGR of 10,20% through 2032, positions wearable sensors as the foundational growth engine for device manufacturers and digital health partners alike.
-
CGM transmitters and data loggers:
CGM transmitters and data loggers occupy a critical enabling role within the Global CGM Market, acting as the communication backbone between sensors, receivers, and cloud-based platforms. These components have evolved from bulky, short-range devices into compact, low-power modules that reliably transmit encrypted glucose data over Bluetooth or other wireless protocols. Their established market position is tied to their indispensable function; without transmitters and loggers, continuous data capture, remote monitoring, and advanced analytics would not be operationally feasible.
The competitive advantage of modern transmitters and data loggers is rooted in battery efficiency, connectivity reliability, and data integrity, which together determine the effective uptime of CGM systems. Many current devices support continuous operation for 3–6 months on a single battery unit or integrated rechargeable cell, while maintaining transmission intervals as low as every 5 minutes with minimal packet loss. Growth in this segment is primarily fueled by the expansion of telehealth and remote patient monitoring programs, where payers and providers increasingly require uninterrupted, high-fidelity data streams to run risk stratification models, population health dashboards, and real-time clinical alerts.
As interoperability standards mature and more CGM platforms integrate with hospital electronic health records and payer portals, transmitters and loggers are being designed for higher data throughput and secure over-the-air firmware updates. This trend supports scaling from thousands to hundreds of thousands of concurrent users within enterprise remote monitoring programs, without sacrificing latency or data quality. The transition toward fully integrated, cloud-native data pipelines creates ongoing replacement and upgrade cycles for transmitter hardware, reinforcing recurring revenue streams and contributing to the sector’s sustained double-digit growth trajectory within the broader CGM market.
-
Standalone CGM receivers and displays:
Standalone CGM receivers and displays represent an important, though gradually shifting, segment within the Global CGM Market, especially among patients who prefer or require a dedicated viewing device instead of relying solely on smartphones. These handheld units provide real-time glucose values, trend arrows, and customizable alerts, ensuring that patients with limited mobile access or digital literacy still benefit from continuous monitoring. Their market position is particularly robust in regions or healthcare settings where smartphone penetration, network coverage, or data plans remain constrained.
The competitive advantage of standalone receivers lies in their medical-grade reliability, long battery life, and focused user interface, which avoids the distractions and variability associated with consumer smartphones. Many devices can operate for multiple days on a single charge while maintaining continuous connectivity to the sensor, and they offer loud audible alarms and high-contrast displays tailored to older adults or visually impaired users. The primary catalyst for ongoing demand is the need to ensure equitable access to CGM therapy across diverse demographic and socioeconomic groups, as payers and public health systems aim to standardize diabetes outcomes irrespective of consumer technology ownership.
While some users are migrating to smartphone-only display models, regulatory requirements and clinical workflows in hospitals, schools, and long-term care facilities continue to favor dedicated receivers for documentation and shared monitoring. In these settings, staff can quickly view glucose trends without needing personal devices, and devices can be standardized across wards to streamline training and maintenance. This institutional value, combined with the role of receivers as a backup display for safety-critical alerts, supports a stable, if slower-growing, revenue stream that complements the faster-expanding app-based interface segment.
-
Integrated CGM-insulin delivery systems:
Integrated CGM-insulin delivery systems, often referred to as automated or semi-automated insulin delivery platforms, represent one of the most dynamic and clinically impactful segments of the Global CGM Market. These systems connect CGM sensors with insulin pumps and control algorithms to adjust basal insulin delivery, and in more advanced configurations, partial or full closed-loop control. Their market position is rapidly strengthening because they move beyond monitoring to active glycemic management, which directly influences long-term complication rates and quality of life for insulin-dependent patients.
The competitive advantage of integrated systems is demonstrated by significant gains in time-in-range and reductions in hypoglycemia compared with standalone pump or sensor use. Many commercial platforms report increases of 10–15 percentage points in time spent within target glucose ranges and notable reductions in nocturnal hypoglycemic episodes, while also lowering the cognitive burden on patients who previously needed to make dozens of dosing decisions per day. The growth catalyst for this segment is the convergence of advanced control algorithms, reliable low-latency data transmission, and favorable reimbursement decisions that recognize the value of automation in reducing total cost of care.
As payers analyze real-world evidence showing fewer hospital admissions and improved HbA1c levels among users of automated insulin delivery, coverage criteria are expanding from narrowly defined type 1 cohorts to broader populations, including some high-risk type 2 patients on intensive insulin therapy. At the same time, manufacturers are launching platforms with modular components, allowing patients to upgrade algorithms or pumps while retaining the same CGM sensor family, which enhances customer retention and lifetime value. These trends, combined with the overall CGM market expansion toward USD 27,60 billion by 2032, position integrated CGM-insulin systems as a central pillar of premium product strategies and partnership-driven innovation between device makers and software firms.
-
CGM data management software and mobile applications:
CGM data management software and mobile applications have emerged as the digital intelligence layer of the Global CGM Market, transforming raw glucose readings into actionable clinical and behavioral insights. These platforms aggregate continuous data, generate trend reports, calculate time-in-range metrics, and often integrate insulin dosing, nutrition logs, and physical activity data. Their market position is increasingly strategic, as they enable remote patient monitoring, virtual coaching, and population-level analytics that are essential for value-based care models and large-scale diabetes management programs.
The competitive advantage of these software solutions lies in their analytics capabilities, user experience, and interoperability with both consumer and clinical systems. Many applications can process thousands of glucose readings per patient per week to identify patterns, flag safety risks, and recommend adjustments, which can reduce out-of-range glucose events by double-digit percentages when paired with clinician oversight. Cloud-based architectures support scalability from small clinics to health systems overseeing tens of thousands of patients, with data dashboards that segment users by risk level, therapy type, and adherence indicators, enabling more efficient allocation of clinician time.
The primary growth catalyst for this segment is the rapid adoption of telemedicine and remote care pathways, where reimbursement codes increasingly recognize remote physiological monitoring and digital therapeutic interventions. Payers and employers are contracting with digital diabetes management programs that rely heavily on CGM-derived data to demonstrate reductions in total medical costs and improved workforce productivity. As the overall market grows at an estimated 10,20% CAGR through 2032, software and mobile applications are expected to capture a rising share of value creation, driving recurring subscription revenues, data-driven service models, and strategic partnerships between CGM manufacturers, digital health companies, and healthcare providers.
-
Professional and clinic-based CGM systems:
Professional and clinic-based CGM systems form a critical diagnostic and titration segment within the Global CGM Market, particularly for patients who are not yet candidates for personal CGM or are undergoing therapeutic reassessment. In this model, healthcare providers deploy CGM sensors for a fixed period, typically 7–14 days, either blinded or unblinded, to capture detailed glycemic profiles that inform medication adjustments and lifestyle interventions. Their market position is strong within endocrinology and primary care practices that manage large numbers of type 2 diabetes patients and prediabetic individuals, where point-in-time HbA1c values fail to reveal daily variability and nocturnal events.
The competitive advantage of professional CGM lies in its ability to generate high-density data over a short timeframe without requiring long-term patient commitment to device ownership. Clinics can reuse receivers and data loggers across many patients, improving capital efficiency, while single-use or limited-use sensors provide precise, continuous readings that reveal postprandial spikes and asymptomatic hypoglycemia. This approach can drive measurable treatment changes; a significant portion of patients undergoing professional CGM experience therapy intensification or de-intensification based on quantitative evidence, which can improve time-in-range and reduce medication costs over subsequent months.
The primary growth catalyst for professional systems is the integration of CGM-based diagnostics into routine diabetes care pathways and payer guidelines, which increasingly recognize the value of periodic intensive monitoring. These systems are also gaining traction in emerging markets where personal CGM affordability remains a barrier, but clinic-based models allow targeted deployment to high-risk patients. As providers scale structured programs that cycle thousands of patients annually through professional CGM assessments, this segment contributes materially to sensor volume growth and serves as a feeder channel, transitioning a proportion of patients into long-term personal CGM use and thereby reinforcing the expansion of the entire CGM value chain.
Market By Region
The global CGM market demonstrates distinct regional dynamics, with performance and growth potential varying significantly across the world's major economic zones.
The analysis will cover the following key regions: North America, Europe, Asia-Pacific, Japan, Korea, China, USA.
-
North America:
North America represents the strategic backbone of the global continuous glucose monitoring market, anchoring innovation, regulatory precedence, and high-value reimbursement models. The United States and Canada serve as the primary demand centers, driven by high diabetes prevalence, strong endocrinology networks, and rapid adoption of sensor-based diabetes management. The region accounts for a substantial portion of global revenue, operating as a mature, stable base that underwrites large-scale R&D, clinical validation, and integration of CGM systems with insulin pumps and digital therapeutics.
Despite its maturity, North America retains meaningful untapped potential in underinsured populations, Medicaid and Medicare segments with partial coverage, and rural communities with limited access to diabetology specialists. Expanding value-based care contracts, enhancing primary care training on CGM interpretation, and integrating CGM data into telehealth platforms can unlock additional growth. Key challenges include pricing pressures from payers, interoperability concerns with legacy electronic health record systems, and the need to improve patient onboarding and adherence.
-
Europe:
Europe plays a pivotal role in the global CGM industry as a diversified, multi-country market with strong public healthcare systems and structured diabetes care pathways. Germany, the United Kingdom, France, Italy, and the Nordics act as core market drivers, supported by national reimbursement frameworks that increasingly recognize CGM as standard of care for type 1 diabetes and complex type 2 cases. The region contributes a significant share of global volume, with growth characterized by steady expansion rather than aggressive acceleration.
Considerable untapped potential exists in Eastern and Southern European countries where reimbursement remains partial, CGM penetration is lower, and fingerstick monitoring still dominates. Opportunities include partnering with national health insurers to demonstrate long-term cost savings, deploying multilingual digital coaching platforms, and expanding hospital-to-home transition programs that include CGM starter kits. Key obstacles involve heterogeneous reimbursement policies, cross-country regulatory nuances, and budget constraints within publicly funded systems that can slow large-scale adoption.
-
Asia-Pacific:
The broader Asia-Pacific region is emerging as one of the most dynamic growth engines for the CGM market, underpinned by rapidly rising diabetes prevalence, urbanization, and increasing healthcare expenditure. Markets such as Australia, India, Southeast Asia, and parts of Oceania drive incremental demand, though starting from a lower installed base than North America or Western Europe. The region collectively accounts for a growing share of the global market and is expected to contribute disproportionately to incremental revenue as the total market advances from USD 13,70 Billion in 2025 toward USD 27,60 Billion by 2032.
Untapped potential is particularly pronounced in large middle-income populations, rural provinces, and public hospital systems where awareness of CGM remains limited and out-of-pocket affordability is a barrier. Strategic opportunities include low-cost sensor portfolios, subscription-based models, and partnerships with telecom and mobile health platforms to deliver app-based glucose analytics in local languages. Key challenges include fragmented regulatory environments, limited reimbursement coverage, uneven distribution channels, and the need for robust physician education to build confidence in continuous data-driven diabetes management.
-
Japan:
Japan stands out within the CGM landscape as a technologically sophisticated yet comparatively conservative market in terms of therapy adoption speed. It is strategically important due to its aging population, high incidence of type 2 diabetes, and strong domestic medical device manufacturing ecosystem. Japan accounts for a meaningful share of Asia-Pacific revenue, functioning as a high-value, mid-growth market where hospital-based diabetology centers and university clinics heavily influence clinical practice guidelines and usage patterns.
Significant untapped potential remains in broader adoption among type 2 diabetes patients managed in community clinics and in expanding CGM use beyond intensive insulin therapy. Opportunities include closer collaboration with the national health insurance system to broaden indications, developing simplified interfaces tailored to older patients, and integrating CGM data with Japan’s advanced health IT infrastructure. Key barriers involve rigorous regulatory processes, cautious guideline revisions, and cultural preferences for established monitoring routines that slow rapid transition from self-monitoring blood glucose to continuous monitoring.
-
Korea:
Korea represents a fast-evolving CGM market with strong digital health capabilities and high smartphone penetration, making it well suited for app-centric glucose monitoring solutions. The country is strategically relevant as a regional innovator and early adopter of connected medical devices within Asia, supported by advanced hospital systems and government interest in digital healthcare. While its absolute market size is smaller than China or Japan, Korea’s share of regional CGM revenue is rising and contributes meaningfully to Asia-Pacific growth momentum.
Untapped potential lies in expanding reimbursement for broader patient segments, increasing penetration among type 2 diabetes patients, and leveraging Korea’s robust consumer electronics ecosystem for locally customized CGM-integrated wearables. Opportunities include partnerships with national insurers for outcome-based reimbursement pilots and integration with telemedicine services that gained traction in recent years. Primary challenges involve pricing sensitivity, strict data privacy regulations governing cloud-based health data, and the need to enhance physician familiarity with interpreting continuous glucose trend metrics outside tertiary care centers.
-
China:
China is one of the most strategically critical CGM markets globally due to its enormous diabetes population and rapidly expanding middle class. The market is transitioning from nascent to scale, with tier 1 cities such as Beijing, Shanghai, Guangzhou, and Shenzhen driving early adoption through tertiary hospitals and private clinics. China’s share of global CGM revenue is increasing quickly, positioning the country as a high-growth engine that will materially influence the overall market trajectory toward USD 15,10 Billion in 2026 and beyond.
Vast untapped potential exists in lower-tier cities, county-level hospitals, and rural regions where diabetes management remains under-resourced and fingerstick testing dominates. Strategic opportunities include local manufacturing and assembly to optimize pricing, collaborations with public health authorities to embed CGM in chronic disease management programs, and integration with dominant local digital ecosystems to deliver data through widely used super apps. Key challenges include complex provincial reimbursement structures, competition from low-cost domestic alternatives, regulatory requirements for data localization, and the need to strengthen clinician training on CGM-driven therapeutic decision-making.
-
USA:
The USA functions as the single most influential national market for CGM, setting benchmarks for technology sophistication, regulatory standards, and commercial scale. It commands a leading share of global revenue, serving as the primary driver of the market’s progression from USD 13,70 Billion in 2025 toward USD 27,60 Billion by 2032, supported by strong uptake across type 1 and intensively managed type 2 diabetes patients. Major integrated delivery networks, pharmacy benefit managers, and private insurers shape access dynamics and formulary positioning.
Despite high penetration among intensively managed patients, substantial untapped potential remains within primary care–managed type 2 diabetes populations, employer-sponsored wellness programs, and underserved rural and inner-city communities. Opportunities include broader coverage for intermittent CGM, simplified sensor insertion systems for primary care settings, and deeper integration of CGM data into population health analytics platforms. Key challenges revolve around reimbursement complexity, prior authorization burdens, disparities in access linked to insurance status, and ongoing pressure to demonstrate cost-effectiveness and long-term outcomes in real-world settings.
Market By Company
The CGM market is characterized by intense competition, with a mix of established leaders and innovative challengers driving technological and strategic evolution.
-
Dexcom Inc.:
Dexcom Inc. occupies a leading position in the continuous glucose monitoring market, with strong brand recognition among endocrinologists, diabetologists, and integrated diabetes management centers. Its CGM platforms are widely adopted in intensive insulin therapy, particularly among Type 1 diabetes patients and technology-forward Type 2 users who demand real-time data and seamless integration with insulin pumps. In 2025, Dexcom is estimated to generate CGM-related revenue of $3.80 billion , reflecting its role as one of the core growth engines in a global market projected at $13.70 billion for that year.
This revenue base corresponds to an estimated global CGM market share of 27.70% in 2025. This level positions Dexcom as a scale leader with strong bargaining power across payers, distributors, and device integration partners. Its share indicates deep penetration in mature markets such as North America and Western Europe, where reimbursement for real-time CGM has become more established, as well as growing traction in Asia-Pacific through partnerships with regional distributors and digital health platforms.
Dexcom’s strategic advantages center on sensor accuracy, user experience, and interoperability with insulin delivery systems. The company has consistently advanced mean absolute relative difference (MARD) performance, enabling more precise glucose trend data that clinicians trust for therapeutic decision-making. At the same time, its cloud-connected ecosystem, mobile app interfaces, and data-sharing capabilities support population health management programs and remote monitoring workflows, which are increasingly important in value-based care models.
A critical differentiator for Dexcom is its deep integration with automated insulin delivery systems from leading pump manufacturers. By enabling closed-loop or hybrid closed-loop configurations, Dexcom locks in multi-year device lifecycles and recurring sensor revenue, creating switching costs for patients and healthcare providers. This integration also supports partnerships with digital therapeutics firms that build predictive algorithms on top of Dexcom’s data streams, further embedding the company into clinical decision support pathways.
From a competitive standpoint, Dexcom leverages rapid innovation cycles and strong regulatory execution to maintain its edge over incumbent and emerging CGM brands. It invests heavily in miniaturization, sensor wear duration improvements, and reduced calibration requirements, all of which directly influence patient adherence and payer cost-effectiveness evaluations. As the global CGM market compounds at an estimated 10.20% CAGR through 2032, Dexcom’s scale and innovation pipeline position it to capture incremental demand from both intensively managed Type 2 patients and expanding primary care CGM use cases.
-
Abbott Laboratories:
Abbott Laboratories is a dominant participant in the global CGM market, with a broad portfolio that spans flash glucose monitoring and real-time CGM systems. Its devices are widely adopted across both developed and emerging markets due to their accessible pricing and pharmacy-channel distribution models. In 2025, Abbott’s CGM-related revenue is estimated at $4.10 billion , making it one of the highest-volume suppliers in a $13.70 billion market.
This revenue is associated with an estimated CGM market share of 29.90% in 2025, placing Abbott marginally ahead of or on par with the other global leader in terms of unit volume and patient reach. The company’s scale is underpinned by strong penetration in the Type 2 diabetes segment, where cost-sensitive payers and national health systems prioritize solutions that can be deployed to large populations. Abbott’s presence in retail pharmacy channels also reduces friction in patient access, expanding the addressable user base beyond specialist clinics.
Abbott’s strategic advantage lies in its ability to deliver CGM and flash monitoring hardware at competitive price points while maintaining clinically acceptable accuracy and reliability. This cost-efficiency stems from high-volume manufacturing, streamlined sensor design, and a global supply chain optimized for consumer health products. As a result, Abbott is often a preferred partner for large-scale health system programs and payer-driven population screening or monitoring initiatives, especially in Europe and Latin America.
The company also differentiates itself through intuitive reader and smartphone interfaces that appeal to newly diagnosed patients and those transitioning from traditional blood glucose monitoring. Its platforms integrate with cloud-based dashboards that facilitate physician review, diabetes education, and adherence monitoring. This makes Abbott a strong contender in primary care and general practitioner settings, where simple workflows and minimal training requirements are essential for CGM adoption.
Looking ahead, Abbott’s broad presence across diagnostics and chronic disease management gives it additional levers in the CGM arena. It can bundle metabolic testing, cardiovascular biomarkers, and glucose monitoring into integrated chronic care programs. This cross-portfolio approach, combined with its large installed base of users, allows Abbott to influence treatment guidelines and reimbursement frameworks in multiple regions. As the overall CGM market grows at a 10.20% CAGR toward $27.60 billion by 2032, Abbott’s cost leadership and mass-market positioning are likely to secure continued share in both developed and emerging economies.
-
Medtronic plc:
Medtronic plc is a key integrated player in the CGM market, especially where continuous glucose monitoring is linked to insulin pump therapy and advanced automated insulin delivery systems. The company leverages its longstanding leadership in insulin pumps to embed proprietary CGM sensors within complete diabetes therapy ecosystems. In 2025, Medtronic’s CGM-related revenue is estimated at $1.70 billion , reflecting significant participation in the $13.70 billion global market.
This revenue corresponds to an estimated 2025 CGM market share of 12.40% . The figure demonstrates that while Medtronic is not the volume leader in stand-alone CGM devices, it maintains strong share in the segment of patients who use integrated insulin pump systems and seek combined hardware from a single vendor. Its share is particularly strong in markets where legacy pump users upgrade within the same ecosystem and value integrated CGM-pump platforms with algorithm-driven insulin dosing.
Medtronic’s strategic advantage stems from its closed-loop system capabilities, where CGM data feeds into insulin delivery algorithms to achieve automated basal adjustments and safety interventions. The company invests heavily in algorithm refinement, hypoglycemia prevention features, and predictive alerts that rely on continuous sensor input. This integrated approach offers a compelling proposition to both patients and clinicians who prioritize tight glycemic control and reduced management burden, especially in pediatric and highly variable glucose profiles.
Medtronic also benefits from its extensive hospital and specialist clinic relationships, which support training, onboarding, and long-term patient support programs. Its global infrastructure in medical devices allows it to coordinate product launches, regulatory approvals, and reimbursement negotiations efficiently across multiple regions. In markets such as the United States, Europe, and parts of Asia-Pacific, this infrastructure gives Medtronic an advantage in securing formulary placements and coverage for premium integrated systems.
As competition in stand-alone CGM intensifies, Medtronic’s differentiation relies on deep integration between sensors, pumps, and digital care platforms. The company is increasingly focused on improving sensor wear duration, comfort, and calibration profiles to match or exceed leading standalone CGM products. Given the CGM market’s projected 10.20% CAGR through 2032, Medtronic is positioned to capture incremental value as more patients shift from multiple daily injections to automated insulin delivery and as payers recognize the long-term cost savings of reduced complications enabled by advanced CGM-pump integration.
-
Senseonics Holdings Inc.:
Senseonics Holdings Inc. plays a specialized role in the CGM market with its focus on implantable continuous glucose monitoring systems. Unlike traditional transcutaneous sensors that require frequent replacement, Senseonics offers long-term implantable sensors designed to remain in situ for several months. In 2025, the company’s CGM-related revenue is estimated at $0.08 billion , representing a niche but strategically important presence in the $13.70 billion global market.
This revenue base translates to an estimated 2025 CGM market share of 0.60% . While relatively small in absolute terms, this share underscores Senseonics’ position as a technology differentiator rather than a mass-market volume leader. Its implantable CGM is particularly attractive to patients who desire discrete, long-wear solutions and to those who have experienced skin irritation or adherence issues with traditional adhesive patch sensors.
Senseonics’ core strategic advantage lies in sensor longevity and the reduced need for frequent device changes. The implantable format can improve adherence by minimizing the operational burden on patients, which is valuable in high-compliance therapy regimens and in populations with limited manual dexterity. Physicians offering advanced diabetes technology services may use Senseonics devices as part of a premium care package for patient segments that prioritize convenience and cosmetic discretion.
The company collaborates with established diabetes care partners to distribute and support its implantable systems, which enhances its reach without requiring an extensive standalone commercial infrastructure. This partnership model helps Senseonics focus resources on R&D, regulatory work, and clinical evidence generation that validates the safety and effectiveness of long-term implantable CGM. As more long-term real-world data accumulates, Senseonics is positioned to engage with payers on differentiated value propositions around adherence and quality-of-life outcomes.
In a market growing at 10.20% CAGR toward 2032, Senseonics may not match the scale of leading wearable CGM players, but it can expand within specialized segments such as highly engaged Type 1 patients, technology enthusiasts, and individuals seeking low-profile monitoring solutions. Its innovation pathway could also open opportunities in combined implantable sensor platforms for metabolic monitoring beyond glucose, thereby enhancing its strategic relevance in long-horizon chronic disease management.
-
F. Hoffmann-La Roche Ltd:
F. Hoffmann-La Roche Ltd maintains a notable presence in diabetes care through its legacy in blood glucose monitoring and digital health platforms, and it leverages this base to participate in the evolving CGM landscape. While not as dominant in CGM hardware as the leading sensor-only companies, Roche plays a strategic role through data integration, software, and selective sensor offerings in certain regions. In 2025, Roche’s CGM-related revenue is estimated at $0.42 billion , reflecting its growing participation within the $13.70 billion market.
This corresponds to an estimated CGM market share of 3.10% in 2025. The share reflects a transitional position, where Roche is leveraging its installed base of blood glucose meters, diabetes management apps, and clinical relationships to migrate users toward continuous monitoring options. It does so through partnerships and region-specific CGM solutions rather than relying solely on in-house sensor platforms.
Roche’s strategic advantage resides in its ecosystem approach to diabetes management. Its digital platforms consolidate data from multiple sources, including CGM devices, traditional glucose meters, insulin delivery tools, and lifestyle tracking applications. This integrated data environment supports advanced analytics, remote patient monitoring, and clinician dashboards that can plug into hospital information systems and primary care networks, giving Roche a systems-level role even when it is not the primary sensor manufacturer.
The company’s extensive experience in diagnostics and laboratory services also supports the development of evidence-based care pathways around CGM utilization. Through clinical decision support tools and therapeutic optimization algorithms, Roche can influence how CGM data are interpreted and acted upon in real-world clinical practice. This positions the company as a key enabler in outcome-based contracts and population health initiatives that rely on longitudinal glucose data.
As the CGM market expands at a 10.20% CAGR to reach $27.60 billion by 2032, Roche is likely to increase its presence by deepening technology partnerships with sensor manufacturers and by embedding CGM data into its broader diagnostic and digital health offerings. This strategy allows the company to generate value from software, analytics, and integrated care solutions, even if it chooses not to compete head-on in high-volume CGM hardware manufacturing.
-
Ascensia Diabetes Care Holdings AG:
Ascensia Diabetes Care Holdings AG, long recognized for its presence in blood glucose monitoring, has been transitioning into the CGM market through collaborations and targeted product launches. The company focuses on providing flexible monitoring solutions that align with the needs of both intensive insulin therapy patients and those in earlier stages of diabetes management. In 2025, Ascensia’s CGM-related revenue is estimated at $0.27 billion within the $13.70 billion global market.
This equates to an estimated CGM market share of 2.00% in 2025. The share indicates that Ascensia is an emerging but not yet dominant player, leveraging its established relationships with endocrinology clinics and pharmacies to introduce CGM products to an existing customer base. Its strategy emphasizes incremental migration from fingerstick-only regimens to hybrid monitoring that incorporates CGM data where clinically and economically justified.
Ascensia’s key strategic advantage lies in its understanding of glucose monitoring workflows and payer requirements gained from years in blood glucose meter markets. The company can design CGM solutions and distribution strategies that align with reimbursement frameworks, carryover formularies, and clinic protocols. This familiarity helps reduce barriers for providers who are transitioning their patient populations from traditional self-monitoring of blood glucose to continuous monitoring paradigms.
In several markets, Ascensia partners with CGM technology innovators to co-market or distribute devices, enabling rapid market entry without the time and capital required for full in-house CGM development. These alliances allow Ascensia to focus on customer support, training, and integration with digital diabetes management platforms, where it can add value based on its service infrastructure and software capabilities.
As the global CGM market grows at 10.20% annually toward 2032, Ascensia is well positioned to capture share among patients who are upgrading from traditional monitoring and among health systems that prefer vendors capable of supporting both legacy and advanced solutions. By offering tiered product portfolios and emphasizing interoperability, Ascensia can act as a bridge between conventional blood glucose monitoring and fully integrated CGM-based care pathways.
-
Insulet Corporation:
Insulet Corporation is best known for its tubeless insulin pump systems, and it plays a strategically important role in the CGM market through integration and ecosystem partnerships rather than stand-alone sensor manufacturing. Its value proposition in CGM centers on enabling seamless connectivity between CGM devices and its automated insulin delivery platforms. In 2025, Insulet’s CGM-related revenue—primarily derived from integrated system value and data services—is estimated at $0.41 billion within the $13.70 billion market.
This translates into an estimated CGM-related market share of 3.00% in 2025. Although Insulet does not dominate in sensor unit volume, its share reflects significant influence in the segment of users who rely on interoperable automated insulin delivery systems. Its platforms are often paired with leading CGM brands, positioning Insulet as a central component of the broader connected diabetes care ecosystem.
Insulet’s strategic advantage lies in its focus on user-centric design, particularly for patients who value tubeless insulin delivery, discretion, and lifestyle flexibility. By creating an insulin delivery system that integrates closely with established CGM devices, Insulet enhances the overall therapeutic experience. Patients and clinicians can benefit from simplified workflows, mobile control, and automated insulin adjustments informed by continuous glucose data.
The company’s partnerships with CGM sensor manufacturers allow it to remain sensor-agnostic and to quickly adapt to improvements in sensor accuracy, wear duration, and connectivity. This flexibility is a key differentiator versus closed systems that rely on proprietary sensors alone. It allows Insulet to participate in multiple geographic markets and payer environments where specific CGM brands have strong reimbursement and regulatory positions.
As the CGM market expands at a projected 10.20% CAGR through 2032, Insulet’s role as a systems integrator and innovator in automated insulin delivery is likely to grow in importance. More patients are expected to adopt hybrid closed-loop and fully closed-loop therapies that rely on continuous glucose data. Insulet can capitalize on this trend by deepening digital health features, refining algorithms, and maintaining close technical alignment with top-tier CGM platforms, thereby sustaining its relevance and revenue contribution within the extended CGM value chain.
-
Ypsomed Holding AG:
Ypsomed Holding AG operates as a significant European-based player in insulin delivery and has been progressively integrating CGM capabilities into its connected diabetes management portfolio. The company focuses on pen systems, patch pumps, and digital platforms that can interface with external CGM solutions to deliver comprehensive therapy management. In 2025, Ypsomed’s CGM-related revenue, driven largely by integrated system sales and data services, is estimated at $0.16 billion in the $13.70 billion global market.
This corresponds to an estimated CGM-related market share of 1.20% in 2025. While this share is modest compared with leading sensor manufacturers, Ypsomed’s influence is significant in specific geographies and segments, particularly in Europe where its delivery devices are well established. Its role is concentrated in facilitating connected care workflows that tie together insulin administration, CGM data streams, and patient support services.
Ypsomed’s strategic advantage lies in its expertise in injection and patch pump technologies and in its agile collaboration model with CGM technology providers. Rather than developing proprietary CGM sensors, the company prioritizes interoperability and user interface innovation. Its digital platforms seek to unify glucose readings, insulin dosing data, and behavioral inputs, thereby supporting clinicians in personalized therapy adjustments and enabling patients to understand the impact of daily choices on glycemic control.
The company’s strong relationships with European healthcare systems and payers allow it to tailor solutions to region-specific reimbursement frameworks and clinical guidelines. This localization enables Ypsomed to position CGM-integrated delivery platforms as cost-effective alternatives to more complex systems, especially for Type 2 patients escalating therapy or for those who prefer pen-based regimens with digital decision support.
As global CGM adoption increases at 10.20% per year toward 2032, Ypsomed stands to benefit from the growing demand for integrated, data-driven diabetes care without bearing the full R&D and manufacturing burden of sensor development. Its strategy of openness and integration allows it to plug into multiple CGM ecosystems, increasing its relevance to both device manufacturers seeking distribution partners and to healthcare providers pursuing interoperable, vendor-neutral solutions.
-
Nemaura Medical Inc.:
Nemaura Medical Inc. is an emerging innovator in the CGM market, with a focus on non-invasive or minimally invasive glucose monitoring technologies. The company targets both diagnosed diabetes patients and prediabetic or wellness-oriented populations through wearable sensor platforms that emphasize comfort and ease of use. In 2025, Nemaura’s CGM-related revenue is estimated at $0.05 billion within the $13.70 billion global CGM market.
This revenue implies an estimated market share of 0.40% in 2025. While this share is relatively small, it reflects early-stage commercialization in niches where traditional, invasive CGM may face adoption barriers. Nemaura’s approach is particularly relevant for individuals at high risk of developing Type 2 diabetes and for those in corporate wellness or preventive health programs who want glucose trend insights without intensive medicalization.
Nemaura’s strategic differentiation is anchored in device comfort, reduced insertion burden, and potential use cases beyond core intensive insulin therapy. By positioning its technology at the intersection of medical CGM and consumer metabolic monitoring, the company seeks to tap into a broader addressable market that includes weight management, metabolic syndrome screening, and digital therapeutics for lifestyle modification. This broader positioning can attract partnerships with employers, payers, and digital health platforms focused on early intervention and chronic disease prevention.
The company also emphasizes mobile-first data delivery and behavioral coaching features, integrating glucose trend insights with actionable recommendations for diet, activity, and stress management. This combination of physiological monitoring and real-time guidance can increase engagement among users who might otherwise find standard CGM systems overly clinical or complex. It also aligns well with subscription-based business models and remote health coaching services.
As the CGM market grows at an anticipated 10.20% CAGR to reach $27.60 billion by 2032, Nemaura could expand by securing regulatory approvals in additional markets and by demonstrating cost-effectiveness in delaying diabetes onset or reducing complications in high-risk populations. Its success will depend on validating accuracy and clinical relevance relative to established CGM systems, but its non-invasive focus provides a distinctive entry point in a crowded field.
-
GlySens Incorporated:
GlySens Incorporated is a development-stage company concentrating on long-term implantable continuous glucose monitoring technologies. Its goal is to provide sensors that can remain functional for extended periods, potentially spanning many months or longer, thereby minimizing maintenance and replacement cycles for patients and clinicians. In 2025, GlySens’ CGM-related revenue is estimated at $0.02 billion , reflecting an early commercialization phase within the $13.70 billion global market.
This equates to an estimated CGM market share of 0.10% in 2025. The limited share is consistent with the company’s focus on clinical development, pilot deployments, and targeted early adopter segments rather than mass-market distribution. Nonetheless, GlySens represents an important vector of innovation in long-wear implantable CGM, a segment that could gain traction as implantation procedures become more standardized and as long-term performance data accumulate.
GlySens’ strategic advantage lies in its potential to redefine the maintenance burden associated with glucose monitoring. By extending sensor longevity significantly beyond traditional wear periods, its technology could appeal to patients who struggle with adherence, who experience skin issues from wearables, or who prefer minimal daily interaction with their devices. This proposition may also resonate in health systems where clinical staff can coordinate implantations with other routine procedures, if regulatory pathways and reimbursement support align.
The company’s focus on highly durable implantable devices requires advanced materials science, biocompatibility optimization, and robust signal processing. Success in these areas could enable GlySens to offer a differentiated cost profile over the life of the device, even if initial implantation costs are higher than those of disposable sensors. From a payer perspective, lower replacement frequency and better adherence could support favorable health economic outcomes.
As the CGM market continues to expand at a 10.20% CAGR through 2032, the niche for implantable, low-maintenance solutions may grow within specific patient cohorts such as long-standing Type 1 diabetics and individuals with high technology adoption willingness. GlySens has the opportunity to become a recognized specialist in this segment, particularly if it can partner with larger device manufacturers or health systems to scale distribution and integrate implantable CGM data into mainstream diabetes management platforms.
-
Tandem Diabetes Care Inc.:
Tandem Diabetes Care Inc. is a prominent player in insulin pump therapy and occupies a strategically important position in the CGM market through interoperable automated insulin delivery systems. Its pump platforms are designed to integrate seamlessly with leading CGM sensors, enabling closed-loop or hybrid closed-loop experiences for patients. In 2025, Tandem’s CGM-related revenue contribution is estimated at $0.34 billion in the context of the $13.70 billion global CGM market.
This revenue indicates an estimated CGM-related market share of 2.50% in 2025. While this share does not reflect standalone sensor sales, it demonstrates Tandem’s importance in the ecosystem that transforms CGM data into actionable insulin dosing decisions. The company has cultivated a strong reputation among technologically engaged patients and clinicians seeking intuitive interfaces, reliable integration, and robust data analytics.
Tandem’s core strategic advantage lies in its user-friendly pump designs, touchscreen interfaces, and software-driven insulin automation features. By focusing on the digital experience and tight integration with CGM data, Tandem delivers systems that lower the cognitive load of diabetes management. Its pumps leverage CGM inputs to adjust basal rates, deliver corrective boluses, and provide predictive alerts, all of which directly depend on the reliability and timeliness of continuous glucose data.
The company actively collaborates with CGM manufacturers to maintain compatibility with new sensor generations and communication protocols. This partner-centric approach ensures that Tandem’s customers can access the latest CGM innovations without changing their insulin delivery hardware. It also positions Tandem as a flexible platform in markets where payer policies or patient preferences favor specific CGM brands.
With the CGM market growing at a 10.20% compound annual rate toward 2032, Tandem stands to gain from the increasing adoption of automated insulin delivery systems among both Type 1 and intensively managed Type 2 patients. As more health systems recognize the clinical and economic benefits of reducing hypoglycemia, time spent out of range, and hospitalizations, demand for integrated CGM-pump solutions is likely to rise. Tandem’s focus on design, interoperability, and continuous software updates gives it a strong competitive footing within this high-value segment of the CGM ecosystem.
-
AgaMatrix Inc.:
AgaMatrix Inc. has a longstanding presence in blood glucose monitoring and has been transitioning toward connected solutions that can align with CGM-enabled care pathways. While its primary business has historically centered on glucose meters and test strips, the company is increasingly investing in digital health tools and selective CGM-related offerings through partnerships and technology development. In 2025, AgaMatrix’s CGM-related revenue is estimated at $0.09 billion within the $13.70 billion global CGM market.
This revenue reflects an estimated CGM market share of 0.70% in 2025. The share underscores AgaMatrix’s early-stage positioning in continuous monitoring, but also its potential to evolve by leveraging existing distribution networks and relationships with primary care providers. It serves segments that are gradually transitioning from episodic fingerstick measurements to continuous or near-continuous monitoring regimes.
AgaMatrix’s strategic advantage stems from its experience in cost-sensitive glucose monitoring solutions and its ability to provide connected devices that interface with smartphones and cloud platforms. This expertise is directly applicable to CGM integration, as patients and clinicians increasingly demand consolidated views of glucose trends, medication adherence, and lifestyle factors. By offering interoperable apps and data platforms, AgaMatrix can participate in CGM-driven care even when it is not the primary sensor manufacturer.
The company’s partnerships with health insurers, pharmacies, and telehealth providers position it to deliver CGM-related services to populations that may be underserved by high-end, premium CGM systems. For example, it can combine lower-cost monitoring tools with digital coaching or remote consultation services, creating scalable models for managing large Type 2 diabetes populations. These models can act as stepping stones to full CGM adoption as reimbursement and infrastructure mature.
As the CGM market grows at a forecasted 10.20% CAGR through 2032, AgaMatrix can expand its role by further integrating CGM data into its digital platforms and by co-developing or distributing sensors tailored to value-focused payer segments. Its ability to balance affordability with connectivity will be critical in capturing share in emerging markets and among health systems that prioritize broad access over premium features, thereby ensuring continued relevance in the evolving landscape of continuous glucose monitoring.
Key Companies Covered
Dexcom Inc.
Abbott Laboratories
Medtronic plc
Senseonics Holdings Inc.
F. Hoffmann-La Roche Ltd
Ascensia Diabetes Care Holdings AG
Insulet Corporation
Ypsomed Holding AG
Nemaura Medical Inc.
GlySens Incorporated
Tandem Diabetes Care Inc.
AgaMatrix Inc.
Market By Application
The Global CGM Market is segmented by several key applications, each delivering distinct operational outcomes for specific industries.
-
Type 1 diabetes management:
Type 1 diabetes management is the most mature and commercially significant application of CGM technology, as patients rely on continuous glucose data to guide intensive insulin therapy throughout the day and night. The core business objective in this segment is to improve glycemic control while minimizing severe hypoglycemia, thereby reducing costly acute events and long-term complications. CGM adoption in this population is justified by quantifiable improvements in time-in-range, which frequently increase by 10,00% to 20,00% compared with traditional self-monitoring, alongside reductions in emergency visits and hospitalizations that translate into measurable cost avoidance for payers.
The unique operational outcome in Type 1 diabetes management lies in the combination of real-time alerts, trend visualization, and data sharing with caregivers, which together reduce the clinical risk associated with rapid glucose fluctuations. Many health systems report that a significant portion of intensively managed Type 1 patients using CGM achieve HbA1c targets that were previously difficult to reach with fingerstick monitoring alone, signaling a clear performance uplift in disease control. The primary growth catalyst for this application is the expanding coverage and reimbursement frameworks in both public and private insurance, which increasingly recognize CGM as standard of care and align with the broader market’s 10,20% CAGR toward USD 27,60 billion by 2032.
Another driver of expansion in this segment is the tight integration of CGM with insulin pumps and automated insulin delivery systems, which are predominantly adopted first in the Type 1 population. These integrated platforms reduce the daily decision-making burden and can cut the time spent managing diabetes by substantial margins, freeing patients and families for other activities. As regulatory agencies approve more advanced closed-loop algorithms and pediatric indications, penetration rates in pediatric and adolescent Type 1 cohorts are rising, further solidifying this application as a core volume and innovation engine for the CGM industry.
-
Type 2 diabetes management:
Type 2 diabetes management represents a rapidly expanding application for CGM, driven by the large and growing global prevalence of insulin-treated and high-risk patients. The primary business objective in this segment is to optimize medication regimens, improve adherence, and prevent costly complications in a population that imposes a substantial economic burden on healthcare systems. CGM delivers a distinct operational outcome compared with traditional monitoring by revealing postprandial excursions and nocturnal events that are often missed, leading to therapy adjustments that can improve time-in-range by double-digit percentages and reduce HbA1c levels in a clinically meaningful way.
Adoption in Type 2 diabetes is increasingly justified by return-on-investment analyses that show reductions in acute care utilization and progression of complications when CGM-guided interventions are implemented. For employers and payers managing large covered populations, programs that deploy CGM to high-risk Type 2 members can generate measurable savings per member per year by reducing hospitalizations, emergency department visits, and disability-related productivity losses. The primary growth catalyst for this application is the shift toward value-based care and risk-sharing contracts, where quantifiable outcomes from CGM data, such as fewer out-of-range glucose days and improved treatment adherence, support performance-based reimbursement structures.
Technological advances and simplified user interfaces are also facilitating adoption among older adults and patients with multiple comorbidities, who may have been reluctant to use more complex diabetes technology in the past. Short-term professional CGM studies are increasingly converting Type 2 patients into long-term personal CGM users when the data reveal actionable patterns, thereby expanding the addressable market. As stakeholders seek scalable solutions for a chronic disease that affects tens of millions of people, Type 2 diabetes management is expected to contribute a growing share of overall CGM sensor volume and revenue growth between 2025, when the market size is expected to reach USD 13,70 billion, and 2032.
-
Gestational diabetes management:
Gestational diabetes management is an application in which CGM delivers critical short-term but high-impact benefits for pregnant individuals and their unborn children. The core business objective is to maintain tight glycemic control during pregnancy to reduce risks such as macrosomia, preeclampsia, cesarean delivery, and neonatal hypoglycemia, all of which carry significant clinical and economic consequences. CGM provides a unique operational outcome by capturing rapid post-meal spikes and nocturnal changes that conventional fasting and occasional postprandial testing may miss, enabling more precise dietary counseling and medication adjustments within a limited timeline.
Quantitatively, programs using CGM in gestational diabetes have reported higher proportions of days within target glucose ranges and fewer episodes of severe hyperglycemia, which correlate with lower rates of obstetric complications and shorter neonatal intensive care stays. For hospitals and payers, these improvements can translate into reductions in length of stay and procedure rates, generating cost savings that help justify the incremental device expense over a short treatment window. The primary growth catalyst for this application is the rising global incidence of gestational diabetes, driven by maternal age trends and obesity rates, combined with increasing clinical guideline support for intensive glycemic monitoring in high-risk pregnancies.
Digital platforms that combine CGM data with obstetric teleconsultations and nutrition coaching are further accelerating adoption by reducing the frequency of in-person clinic visits, which is particularly valuable in rural or underserved areas. These hybrid care models allow clinicians to adjust therapy remotely based on daily data rather than waiting for periodic lab results, improving responsiveness and patient satisfaction. As more obstetric and maternal-fetal medicine practices incorporate CGM into standardized gestational diabetes pathways, this application will continue to strengthen its role as a specialty-driven yet economically meaningful contributor to the overall CGM market.
-
Pre-diabetes and metabolic health monitoring:
Pre-diabetes and metabolic health monitoring is an emerging application that extends CGM beyond traditional disease management into preventive and wellness-oriented use cases. The central business objective is to identify dysglycemia early, quantify the impact of lifestyle choices, and prevent or delay progression from pre-diabetes to overt diabetes, which has significant long-term cost implications. CGM delivers a distinctive operational outcome in this context by providing real-time feedback on how specific foods, sleep patterns, and exercise sessions influence glucose variability, allowing individuals and coaches to tailor interventions with data-driven precision.
Although many users in this segment may not require continuous, year-round monitoring, intermittent CGM use over several weeks can reveal patterns that are not evident from fasting glucose or HbA1c tests alone. Corporate wellness programs and digital metabolic health platforms that incorporate CGM data have reported meaningful improvements in weight, time-in-range, and insulin sensitivity markers for a significant portion of participants, which can lower projected future healthcare costs and absenteeism. The strategic growth catalyst here is the convergence of consumer interest in personalized health optimization with payer and employer efforts to reduce long-term cardiometabolic risk, creating an attractive market for subscription-based digital services built around CGM insights.
Technology companies are leveraging CGM-derived datasets to develop recommendation engines, scoring systems, and behavior change programs that can be deployed at scale through mobile applications. These solutions appeal to health-conscious consumers, athletes, and individuals with family histories of diabetes who are willing to self-fund CGM use in the absence of traditional reimbursement. As the overall CGM market grows to an expected USD 15,10 billion in 2026 and beyond, pre-diabetes and metabolic health monitoring is likely to command a growing share of incremental demand, particularly in higher-income markets where preventive health spending is robust.
-
In-hospital and critical care glucose monitoring:
In-hospital and critical care glucose monitoring is a high-acuity application where CGM addresses the operational need for precise, continuous glycemic control in patients with complex clinical conditions. The business objective is to reduce complications associated with both hyperglycemia and hypoglycemia in intensive care units, surgical wards, and high-dependency areas, which can drive up mortality, length of stay, and costs. Traditional intermittent blood draws and point-of-care testing can miss rapid fluctuations, whereas CGM offers near-continuous data that support tighter glucose management protocols and more efficient use of nursing resources.
From an operational perspective, deploying CGM in hospital settings can reduce the frequency of fingerstick checks per patient per day, freeing nursing time and potentially lowering consumable costs, while also improving the timeliness of insulin adjustments. Quantitative studies have shown that better-controlled in-hospital glucose profiles are associated with shorter stays and fewer infections, which can produce substantial savings per admission when scaled across high-volume institutions. The main growth catalyst in this application is the increasing recognition of glycemic control as a quality metric, combined with technology advances that adapt CGM devices for use in the presence of interfering factors such as edema, vasopressors, or fluctuating perfusion.
Recent global health events have also highlighted the operational challenges of frequent bedside testing in infectious disease wards, motivating hospitals to explore CGM as a way to minimize staff exposure while maintaining adequate monitoring. Integration of CGM feeds into existing clinical information systems and electronic health records allows real-time dashboards and automated alerts for out-of-range values, supporting proactive interventions. As procurement teams evaluate capital and operational expenditures against measurable gains in safety and workflow efficiency, in-hospital and critical care applications are expected to become a more material contributor to CGM adoption, particularly in advanced healthcare systems.
-
Remote patient monitoring and telehealth-based diabetes care:
Remote patient monitoring and telehealth-based diabetes care is one of the fastest-growing applications of CGM, reflecting a broader transformation of care delivery models. The core business objective is to extend high-quality diabetes management beyond the clinic by enabling clinicians, coaches, and care teams to monitor patients continuously and intervene between visits. CGM is uniquely suited to this application because it generates high-frequency data streams that can be analyzed in near real time, leading to operational outcomes such as reduced unplanned visits, fewer acute events, and more efficient allocation of clinical resources.
Programs that integrate CGM into remote monitoring workflows often demonstrate significant reductions in out-of-range glucose days and associated hospitalizations, which can deliver attractive return-on-investment for payers and risk-bearing provider organizations. For instance, analytics platforms can triage thousands of patients and flag only those whose time-in-range has deteriorated by a predefined percentage, allowing care teams to prioritize outreach where it will have the greatest impact. The primary growth catalyst for this application is the expansion of reimbursement for remote physiological monitoring and telehealth encounters, which monetizes the continuous data flows generated by CGM and supports new subscription and service-based revenue models.
Additionally, patient demand for convenient, virtual care has accelerated the deployment of CGM-enabled telehealth programs, particularly in regions where travel time and access barriers are significant. Digital health companies are partnering with CGM manufacturers to bundle sensors with coaching, algorithm-driven insights, and outcome-based contracts that align the interests of patients, providers, and payers. As the overall market advances toward USD 27,60 billion by 2032, remote monitoring and telehealth-based applications are expected to play a pivotal role in scaling CGM adoption while helping health systems manage large diabetic populations with constrained clinical staffing.
Key Applications Covered
Type 1 diabetes management
Type 2 diabetes management
Gestational diabetes management
Pre-diabetes and metabolic health monitoring
In-hospital and critical care glucose monitoring
Remote patient monitoring and telehealth-based diabetes care
Mergers and Acquisitions
The continuous glucose monitoring (CGM) market is experiencing intensified mergers and acquisitions as strategic buyers and financial sponsors compete for sensor, algorithm, and connectivity assets. Deal flow over the last 24 months reflects accelerating consolidation, with acquirers seeking scale, integrated diabetes management platforms, and predictive analytics capabilities. This activity aligns with expectations for the market to expand from USD 13.70 Billion in 2025 to USD 27.60 Billion by 2032, supported by a 10.20% CAGR and rising adoption in Type 2 diabetes and hospital settings.
Major M&A Transactions
Dexcom – SmallSense Analytics
Accelerates development of AI-driven glucose prediction and decision-support algorithms for insulin titration.
Abbott Laboratories – Nordic CGM Systems
Expands sensor manufacturing capacity and strengthens reimbursement access across Northern Europe’s public payers.
Medtronic – BetaLoop Digital Health
Integrates closed-loop software to enhance interoperability with insulin pumps and smart pens globally.
Roche – GlucoTrack Cloud
Adds cloud-based data sharing and clinician dashboards to support remote diabetes population management.
Ascensia Diabetes Care – AsiaGlu Sensors
Secures low-cost disposable sensor technology tailored for high-volume Asian emerging markets.
Insulet – MicroPatch Biotech
Gains next-generation microneedle patch form factor to improve wearability and user adherence.
Siemens Healthineers – HospitalGlu Monitoring
Builds an inpatient glycemic management platform integrated with lab and EMR workflows.
Terumo – SmartGlyco Japan
Strengthens domestic CGM portfolio with Bluetooth-enabled sensors for cardiometabolic clinics.
Recent CGM acquisitions are tightening market concentration as established players bolt on sensor and software innovators rather than allowing standalone competitors to scale. This favors incumbents with large installed bases, enabling faster cross-selling of devices and data services. Smaller CGM start-ups increasingly position themselves as technology providers rather than full-stack competitors, which channels innovation but raises barriers for new independent entrants. As a result, bargaining power with payers and distributors is gradually consolidating among a few global platforms.
Valuation multiples in CGM transactions remain elevated, with many deals implicitly pricing in the 10.20% CAGR and premium for recurring consumable revenue. Targets with proven sensor accuracy, long wear-time, and regulatory approvals in multiple geographies command higher revenue multiples than those with only prototype technologies. Conversely, hospital-focused CGM assets and B2B data platforms often trade on strategic value rather than current sales, reflecting expectations for accelerated adoption in acute-care glycemic management.
Strategically, acquirers emphasize vertical integration of hardware, software, and data analytics to build closed-loop or decision-support ecosystems. This integrated posture improves patient stickiness, supports subscription models, and facilitates value-based contracts with payers and providers. At the same time, many buyers pursue horizontal expansion across Type 1, Type 2, gestational diabetes, and metabolic syndrome, ensuring their portfolios cover both intensive insulin users and broader cardiometabolic risk populations.
Regionally, North America and Western Europe dominate deal volumes, driven by reimbursement clarity, robust telehealth infrastructure, and high sensor penetration. However, several recent acquisitions target India, Southeast Asia, and Latin America indirectly by acquiring low-cost sensor platforms and regional manufacturing capabilities. These deals aim to localize production, meet pricing constraints, and navigate diverse regulatory frameworks while still feeding into global product roadmaps.
Technology themes shaping the mergers and acquisitions outlook for CGM Market include AI-based predictive algorithms, factory-calibrated sensors, and integration with digital therapeutics and electronic medical records. Buyers prioritize assets that reduce calibration burden, extend wear-time, and enable real-time clinical decision support. Acquisitions of cloud platforms and cybersecurity capabilities also reflect growing importance of secure data sharing between patients, endocrinologists, and hospital systems.
Competitive LandscapeRecent Strategic Developments
In January 2024, Dexcom announced a strategic partnership and integration expansion with leading smartphone and wearable platforms, deepening interoperability of its G7 system across iOS and Android ecosystems. This expansion enables broader real-time data sharing with digital therapeutics and telehealth providers, intensifying competitive pressure on rivals to match seamless connectivity and user experience in the continuous glucose monitoring market.
In March 2024, Abbott entered a strategic collaboration and investment agreement with multiple insulin pump and automated insulin delivery manufacturers to further integrate its FreeStyle Libre 3 sensors into closed-loop ecosystems. This strategic investment reinforces Abbott’s position in integrated diabetes management, accelerates the shift toward fully automated insulin dosing and raises the integration bar for new CGM entrants and regional players.
In June 2023, Medtronic completed a targeted portfolio expansion through the commercial rollout of its next-generation Guardian 4 CGM in key North American and European markets. This expansion, focused on reduced calibration requirements and enhanced sensor longevity, helped Medtronic regain share in advanced hybrid closed-loop systems and intensified innovation cycles among competitors pursuing lower burden CGM solutions.
SWOT Analysis
-
Strengths:
The global continuous glucose monitoring market benefits from strong underlying demand drivers, including rising diabetes prevalence, an aging population, and the clinical need for tighter glycemic control to reduce hospitalization and complication rates. CGM systems provide real-time glucose data, trend analysis, and hypoglycemia alerts that outperform traditional self-monitoring of blood glucose, which materially improves time-in-range and reduces acute events. Reimbursement adoption in North America and parts of Europe, combined with user-friendly wearables, smartphone integrations, and cloud-based analytics, supports recurring sensor revenue and high switching costs. With the market estimated at USD 13,70 Billion by 2025 and growing at a 10,20% CAGR toward USD 27,60 Billion by 2032 according to ReportMines, manufacturers benefit from scalable sensor production, data-driven product improvements, and expanding use cases in type 1, insulin-treated type 2, and gestational diabetes segments.
-
Weaknesses:
Despite strong growth, the CGM market faces structural weaknesses such as high device and consumable costs, which limit penetration in price-sensitive regions and among uninsured or underinsured patients. Sensor wear-time constraints, occasional connectivity issues, and the need for regular replacement contribute to user fatigue and adherence challenges, especially outside intensively managed type 1 diabetes populations. Many healthcare systems still lack standardized reimbursement for non–insulin-treated type 2 patients, constraining volume expansion and limiting the economic case for payers focused on short-term budgets rather than long-term outcomes. The market is also concentrated in a few multinational manufacturers with proprietary platforms, leading to interoperability gaps, vendor lock-in, and slower adoption of open-protocol ecosystems that could broaden clinical use in primary care and emerging markets.
-
Opportunities:
The CGM industry has substantial expansion headroom in insulin-treated and non–insulin-treated type 2 diabetes populations, where current penetration remains a small fraction of the addressable patient base. Integration with automated insulin delivery systems, smart insulin pens, and AI-driven decision support tools can transform CGM devices into central nodes of fully digital diabetes management platforms, creating new value in population health, remote patient monitoring, and risk-based contracting. As the market grows from an estimated USD 15,10 Billion in 2026 toward USD 27,60 Billion by 2032 at a 10,20% CAGR, vendors can target high-growth regions in Asia-Pacific, Latin America, and the Middle East through localized manufacturing, tiered pricing models, and partnerships with public health programs. Additional opportunities exist in expanding CGM use for prediabetes, bariatric surgery follow-up, sports performance, and hospital in-patient monitoring, which can diversify revenue streams beyond traditional endocrinology channels.
-
Threats:
The CGM market faces threats from intensifying price competition, potential reimbursement cuts, and stricter cost-effectiveness assessments by health technology evaluation agencies that could pressure margins and limit premium pricing. Regulatory scrutiny of data security, cybersecurity, and algorithm transparency is increasing as CGM systems become more connected and integrated with insulin pumps, creating compliance risks and potential launch delays. Emerging competitors from low-cost regions and adjacent digital health companies may introduce disruptive sensor technologies, non-invasive solutions, or subscription-based virtual care bundles that shift value away from hardware. Macroeconomic pressures, currency volatility, and supply chain disruptions in critical components such as semiconductors and sensor materials can affect production continuity and inventory strategies, while any high-profile product recall or cybersecurity incident could undermine patient and clinician trust across the entire CGM ecosystem.
Future Outlook and Predictions
The global continuous glucose monitoring market is expected to maintain a strong upward trajectory over the next decade, supported by robust volume growth across both type 1 and insulin-treated type 2 diabetes populations. Using ReportMines data as an anchor, the market is projected to rise from USD 13,70 Billion in 2025 to USD 15,10 Billion in 2026 and reach USD 27,60 Billion by 2032, implying a sustained CAGR of 10,20 percent. This growth profile suggests that CGM will become the standard of care for intensively managed diabetes, with finger-stick testing progressively relegated to niche or backup roles.
Technology evolution will be characterized by smaller, more accurate, and longer-wear sensors that reduce user burden while enabling continuous data streaming. Manufacturers are likely to prioritize factory-calibrated sensors, 14–21 day wear times, and improved adhesion and comfort features that address current pain points such as skin irritation and sensor loss. These advances will be underpinned by incremental improvements in enzyme chemistry, microelectronics, and power management, allowing more reliable performance in challenging conditions such as exercise and variable temperatures.
Over the next 5–10 years, CGM devices will increasingly function as data hubs at the center of closed-loop and decision-support ecosystems. Wider integration with automated insulin delivery systems, smart pens, and AI-driven dosing algorithms will accelerate adoption by demonstrating measurable gains in time-in-range and reductions in severe hypoglycemia. Cloud-based analytics will enable clinicians to manage larger patient panels remotely, while payers will use aggregated real-world data to design outcomes-based contracts that reward sustained glycemic improvements.
Regulatory and reimbursement policies will play a pivotal role in shaping market penetration, particularly for non–insulin-treated type 2 diabetes and prediabetes segments. As more evidence accumulates on reduced hospitalization, fewer diabetes complications, and lower overall healthcare costs, a growing number of public and private payers are expected to expand coverage criteria. This shift will be reinforced by updated clinical practice guidelines that increasingly reference CGM for risk stratification, therapy intensification, and monitoring of high-risk populations such as pregnant women with gestational diabetes.
Competitive dynamics are likely to intensify as incumbent manufacturers face pressure from new entrants, lower-cost regional suppliers, and digital health companies offering integrated virtual diabetes clinics. Price competition and tender-based procurement will incentivize modular, interoperable platforms and tiered product portfolios tailored to different income levels and care settings. Companies that combine reliable sensors with compelling software, telehealth workflows, and value-based pricing models will be best positioned to capture share in this expanding, data-centric CGM landscape.
Table of Contents
- Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global CGM Annual Sales 2017-2028
- 2.1.2 World Current & Future Analysis for CGM by Geographic Region, 2017, 2025 & 2032
- 2.1.3 World Current & Future Analysis for CGM by Country/Region, 2017,2025 & 2032
- 2.2 CGM Segment by Type
- Wearable CGM sensors
- CGM transmitters and data loggers
- Standalone CGM receivers and displays
- Integrated CGM-insulin delivery systems
- CGM data management software and mobile applications
- Professional and clinic-based CGM systems
- 2.3 CGM Sales by Type
- 2.3.1 Global CGM Sales Market Share by Type (2017-2025)
- 2.3.2 Global CGM Revenue and Market Share by Type (2017-2025)
- 2.3.3 Global CGM Sale Price by Type (2017-2025)
- 2.4 CGM Segment by Application
- Type 1 diabetes management
- Type 2 diabetes management
- Gestational diabetes management
- Pre-diabetes and metabolic health monitoring
- In-hospital and critical care glucose monitoring
- Remote patient monitoring and telehealth-based diabetes care
- 2.5 CGM Sales by Application
- 2.5.1 Global CGM Sale Market Share by Application (2020-2025)
- 2.5.2 Global CGM Revenue and Market Share by Application (2017-2025)
- 2.5.3 Global CGM Sale Price by Application (2017-2025)
Frequently Asked Questions
Find answers to common questions about this market research report
Company Intelligence
Key Companies Covered
View detailed company rankings, SWOT insights, and strategic profiles for this report.